Skip to main content
LungLife AI, INC logo

LungLife AI, INC — Investor Relations & Filings

Ticker · LLAI ISIN · USU5500L1045 LEI · 549300VBVDIF0Y3OVI38 IL Human health and social work activities
Filings indexed 85 across all filing types
Latest filing 2024-10-25 Board/Management Inform…
Country US United States of America
Listing IL LLAI

About LungLife AI, INC

https://lunglifeai.com

LungLife AI, INC. is a diagnostic company focused on developing clinical solutions for the early detection of lung cancer. Its principal product, the LungLB® test, is a minimally invasive liquid biopsy that analyzes biomarkers from a simple blood draw. Enhanced by artificial intelligence and machine learning, the test is designed to provide clinicians with additional information to aid in the evaluation and management of indeterminate lung nodules. The company's objective is to improve clinical decision-making and facilitate earlier diagnosis, thereby impacting patient outcomes for the deadliest form of cancer globally.

Recent filings

Filing Released Lang Actions
Directorate Change
Board/Management Information Classification · 100% confidence The document is an official announcement from LungLife AI regarding the resignation of a non-executive director, James McCullough. The title 'Directorate Change' and the content detailing the departure of a board member clearly align with the definition for Board/Management Information (MANG).
2024-10-25 English
Cancellation & Reissue Share Options, PDMR Notice
Director's Dealing Classification · 95% confidence The document is a regulatory announcement (RNS) regarding the cancellation and re-issue of share options for Persons Discharging Managerial Responsibilities (PDMRs), specifically the CEO and CFO. It explicitly includes the required disclosure tables under the Market Abuse Regulation (MAR). While it involves directors, it is a formal notification of share-based incentive transactions rather than a simple personal trade, and it fits the 'Director's Dealing' (DIRS) category as it reports transactions by company executives.
2024-10-22 English
Options Cancellation and Re-issuance
Regulatory Filings Classification · 98% confidence The document is an RNS announcement from LungLife AI regarding the cancellation and re-issuance of share options for Executive Directors and employees. This relates directly to executive compensation and incentive structures, which falls under the category of Remuneration Information (DEF 14A). While it involves share options, it is specifically framed as a Remuneration Committee decision to address executive incentivization.
2024-10-04 English
LungLB® publication in peer-reviewed journal
Regulatory Filings Classification · 98% confidence The document is a press release distributed via the London Stock Exchange's RNS (Regulatory News Service). It announces the acceptance of a scientific study for publication in a peer-reviewed journal regarding the company's LungLB test. Since this is a general corporate announcement regarding business operations and scientific milestones that does not fit into specific categories like financial reports, dividends, or board changes, it is classified as a general regulatory filing.
2024-10-02 English
Data Supporting LungLB to be Presented at the AMP
Regulatory Filings Classification · 98% confidence The document is a press release distributed via the RNS (Reach) service. It announces that LungLife AI has had two abstracts accepted for presentation at an upcoming medical conference (Association for Molecular Pathology). It does not contain financial statements, board changes, or regulatory filings, but rather serves as a corporate update on research and development progress. Since it does not fit into specific categories like 'Earnings Release' or 'Investor Presentation', and is a general corporate announcement, it falls under the 'Regulatory Filings' (RNS) category as a catch-all for miscellaneous corporate news.
2024-09-02 English
Half-year Report
Interim / Quarterly Report Classification · 100% confidence The document is a 'Half-year Report' for LungLife AI, Inc. for the six months ended 30 June 2024. It contains comprehensive financial highlights (cash position, equity funding, cash outflow, EBITDA loss) and a detailed Chairman's Statement discussing strategic updates, commercialization readiness, clinical validation results, and future outlook. As it covers a period shorter than a full fiscal year and includes substantive financial data and management analysis, it is classified as an Interim/Quarterly Report. H1 2024
2024-08-22 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.